These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35942337)

  • 1. COVID-19, ESG investing, and the resilience of more sustainable stocks: Evidence from European firms.
    Cardillo G; Bendinelli E; Torluccio G
    Bus Strategy Environ; 2022 Jun; ():. PubMed ID: 35942337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of ESG performance on the stock market during the COVID-19 Pandemic - Evidence from Japan.
    Liu L; Nemoto N; Lu C
    Econ Anal Policy; 2023 Jun; ():. PubMed ID: 38620119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corporate sustainability performance, stock returns, and ESG indicators: fresh insights from EU member states.
    Ye C; Song X; Liang Y
    Environ Sci Pollut Res Int; 2022 Dec; 29(58):87680-87691. PubMed ID: 35819677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Firms' COVID-19 Pandemic Exposure and Corporate Cash Policy: Evidence from China.
    He Z; Suardi S; Wang K; Zhao Y
    Econ Model; 2022 Nov; 116():105999. PubMed ID: 36032988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leadership in a pandemic: Do more able managers keep firms out of trouble?
    Nguyen HT; Pham MH; Truong C
    J Behav Exp Finance; 2023 Mar; 37():100781. PubMed ID: 36568125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it good to hold more cash before the pandemic? A case of Taiwanese firms.
    Wu SW; Nguyen MT; Mai NT; Tsai JF
    Heliyon; 2023 Jun; 9(6):e16050. PubMed ID: 37260906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of ESG performance during times of COVID-19 pandemic.
    Gao M; Geng X
    Sci Rep; 2024 Jan; 14(1):2553. PubMed ID: 38297089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does sustainability activities performance matter during financial crises? Investigating the case of COVID-19.
    Yoo S; Keeley AR; Managi S
    Energy Policy; 2021 Aug; 155():112330. PubMed ID: 35722223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Corporate Social Responsibility investing a free lunch? The relationship between ESG, tail risk, and upside potential of stocks before and during the COVID-19 crisis.
    Lööf H; Sahamkhadam M; Stephan A
    Financ Res Lett; 2022 May; 46():102499. PubMed ID: 36569340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESG performance and stock prices: evidence from the COVID-19 outbreak in China.
    Li Z; Feng L; Pan Z; Sohail HM
    Humanit Soc Sci Commun; 2022; 9(1):242. PubMed ID: 35874283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An empirical study of supply chain sustainability with financial performances of Indian firms.
    Sachin N; Rajesh R
    Environ Dev Sustain; 2022; 24(5):6577-6601. PubMed ID: 34393619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESG did not immunize stocks during the COVID-19 crisis, but investments in intangible assets did.
    Demers E; Hendrikse J; Joos P; Lev B
    J Bus Finance Account; 2021; 48(3-4):433-462. PubMed ID: 34230747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Does Firm ESG Performance Impact Financial Constraints? An Experimental Exploration of the COVID-19 Pandemic.
    Zhang D; Wang C; Dong Y
    Eur J Dev Res; 2023; 35(1):219-239. PubMed ID: 35002102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pandemic effect on corporate financial asset holdings: Precautionary or return-chasing?
    Gao H; Wen H; Wang X
    Res Int Bus Finance; 2022 Dec; 62():101750. PubMed ID: 35996462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Environmental stocks, CEO health risk and COVID-19.
    Fernández-Méndez C; Pathan S
    Res Int Bus Finance; 2022 Jan; 59():101509. PubMed ID: 34522059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is cash the panacea of the COVID-19 pandemic: Evidence from corporate performance.
    Zheng M
    Financ Res Lett; 2022 Mar; 45():102151. PubMed ID: 35221815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corporate immunity to the COVID-19 pandemic.
    Ding W; Levine R; Lin C; Xie W
    J financ econ; 2021 Aug; 141(2):802-830. PubMed ID: 34580557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Issuing bonds during the Covid-19 pandemic: Was there an ESG premium?
    Ferriani F
    Int Rev Financ Anal; 2023 Jul; 88():102653. PubMed ID: 37070084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Environmental, social, and governance (ESG) performance and financial outcomes: Analyzing the impact of ESG on financial performance.
    Chen S; Song Y; Gao P
    J Environ Manage; 2023 Nov; 345():118829. PubMed ID: 37688968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESG Performance and Stock Price Volatility in Public Health Crisis: Evidence from COVID-19 Pandemic.
    Zhou D; Zhou R
    Int J Environ Res Public Health; 2021 Dec; 19(1):. PubMed ID: 35010460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.